← Leaderboards
William F Symmans
University Of Tx Md Anderson Can Ctr
$2,674,110
Attributed
$2,674,110
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $369.7K · FY2006–24$500K$375K$250K$125K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,674,110 · 3
By mechanism
U01$1,644,640 · 1
UH3$721,527 · 1
R21$307,943 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Ken H. Young$1,790,016
- Liuqing Yang$6,260,577
- Khandan Keyomarsi$13,000,468
- Jyotika Sharma$8,517,056
- Powel Brown$21,822,596
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorGene ExpressionHormone TherapyEsr1 GeneEndocrineEstrogen ReceptorsMeasurementIndexingScienceParaffin EmbeddingSamplingPrognosticPerformanceProgesterone ReceptorsSpecific BiomarkersLaboratoriesGenetic TranscriptionMalignant Breast NeoplasmReportingFormalinClia CertifiedErbb2 GeneMalignant NeoplasmsReproducibility
Grant awards (9)
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial$351,809
UH3 · FY2024 · CA · contact PI
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial$369,718
UH3 · FY2023 · CA · contact PI
Integrating Biospecimen Science Into The Development Of RNA-Based Clinical Assays For Patients With Metastatic Breast Cancer$322,770
U01 · FY2021 · CA · contact PI
Integrating Biospecimen Science Into The Development Of RNA-Based Clinical Assays For Patients With Metastatic Breast Cancer$325,254
U01 · FY2020 · CA · contact PI
Integrating Biospecimen Science Into The Development Of RNA-Based Clinical Assays For Patients With Metastatic Breast Cancer$317,985
U01 · FY2019 · CA · contact PI
Integrating Biospecimen Science Into The Development Of RNA-Based Clinical Assays For Patients With Metastatic Breast Cancer$330,457
U01 · FY2018 · CA · contact PI
Integrating Biospecimen Science Into The Development Of RNA-Based Clinical Assays For Patients With Metastatic Breast Cancer$348,174
U01 · FY2017 · CA · contact PI
ER Reporter Genes To Predict Response To Endocrine Therapy$138,256
R21 · FY2007 · CA · contact PI
ER Reporter Genes To Predict Response To Endocrine Therapy$169,687
R21 · FY2006 · CA · contact PI